Found: 41
Select item for more details and to access through your institution.
A Placebo‐Controlled Phase I Study in Healthy Subjects Assessing NVG‐291, which Targets CNS Receptor Protein Tyrosine Phosphatase Sigma (PTPσ).
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2022, v. 18, n. 10, p. 1, doi. 10.1002/alz.059663
- By:
- Publication type:
- Article
A Peanut Agglutinin Binding Glycoprotein in CNS Myelin and Oligodendrocytes.
- Published in:
- Annals of the New York Academy of Sciences, 1988, v. 540, n. 1, p. 409, doi. 10.1111/j.1749-6632.1988.tb27118.x
- By:
- Publication type:
- Article
Oligodendrocyte‐myelin glycoprotein is present in lipid rafts and caveolin‐1‐enriched membranes.
- Published in:
- Glia, 2005, v. 52, n. 3, p. 219
- By:
- Publication type:
- Article
Schwann cell caveolin-1 expression increases during myelination and decreases after axotomy.
- Published in:
- Glia, 2002, v. 38, n. 3, p. 191, doi. 10.1002/glia.10063
- By:
- Publication type:
- Article
Long-term safety and efficacy of erenumab in patients with chronic migraine: Results from a 52-week, open-label extension study.
- Published in:
- 2020
- By:
- Publication type:
- journal article
The spectrum of response to erenumab in patients with chronic migraine and subgroup analysis of patients achieving ≥50%, ≥75%, and 100% response.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Long-term tolerability and nonvascular safety of erenumab, a novel calcitonin gene-related peptide receptor antagonist for prevention of migraine: A pooled analysis of four placebo-controlled trials with long-term extensions.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Long-term safety and tolerability of erenumab: Three-plus year results from a five-year open-label extension study in episodic migraine.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Efficacy and safety of erenumab (AMG334) in episodic migraine patients with prior preventive treatment failure: A subgroup analysis of a randomized, double-blind, placebo-controlled study.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Migraine-related disability, impact, and health-related quality of life among patients with episodic migraine receiving preventive treatment with erenumab.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Efficacy and safety of erenumab (AMG334) in chronic migraine patients with prior preventive treatment failure: A subgroup analysis of a randomized, double-blind, placebo-controlled study.
- Published in:
- 2018
- By:
- Publication type:
- journal article
ARISE: A Phase 3 randomized trial of erenumab for episodic migraine.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Early onset of efficacy with erenumab for migraine prevention in Japanese patients: Analysis of two randomized, double‐blind, placebo‐controlled studies.
- Published in:
- Brain & Behavior, 2022, v. 12, n. 3, p. 1, doi. 10.1002/brb3.2526
- By:
- Publication type:
- Article
Neurophilins and the nervous system.
- Published in:
- 1999
- By:
- Publication type:
- Editorial
Correction to: A Multi‑Center, Open‑Label, Pharmacokinetic Drug Interaction Study of Erenumab and a Combined Oral Contraceptive in Healthy Females.
- Published in:
- 2019
- By:
- Publication type:
- corrected article
A Multi-Center, Open-Label, Pharmacokinetic Drug Interaction Study of Erenumab and a Combined Oral Contraceptive in Healthy Females.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Reduction in migraine pain intensity in patients treated with erenumab: A post hoc analysis of two pivotal randomized studies.
- Published in:
- Cephalalgia, 2021, v. 41, n. 14, p. 1458, doi. 10.1177/03331024211028966
- By:
- Publication type:
- Article
Randomised, controlled trial of erenumab for the prevention of episodic migraine in patients from Asia, the Middle East, and Latin America: The EMPOwER study.
- Published in:
- Cephalalgia, 2021, v. 41, n. 13, p. 1285, doi. 10.1177/03331024211024160
- By:
- Publication type:
- Article
A phase 2, randomized, double-blind, placebo-controlled trial of AMG 301, a pituitary adenylate cyclase-activating polypeptide PAC1 receptor monoclonal antibody for migraine prevention.
- Published in:
- Cephalalgia, 2021, v. 41, n. 1, p. 33, doi. 10.1177/0333102420970889
- By:
- Publication type:
- Article
Reversion from chronic migraine to episodic migraine following treatment with erenumab: Results of a post-hoc analysis of a randomized, 12-week, double-blind study and a 52-week, open-label extension.
- Published in:
- Cephalalgia, 2021, v. 41, n. 1, p. 6, doi. 10.1177/0333102420973994
- By:
- Publication type:
- Article
Suppression of mitoxantrone cardiotoxicity in multiple sclerosis patients by dexrazoxane.
- Published in:
- Annals of Neurology, 2006, v. 59, n. 1, p. 206, doi. 10.1002/ana.20747
- By:
- Publication type:
- Article
Caveolin-1 expression in Schwann cells.
- Published in:
- Glia, 1999, v. 27, n. 1, p. 39, doi. 10.1002/(SICI)1098-1136(199907)27:1<39::AID-GLIA5>3.0.CO;2-#
- By:
- Publication type:
- Article
Efficacy of Disease-Modifying Therapies in Relapsing Remitting Multiple Sclerosis: A Systematic Comparison.
- Published in:
- European Neurology, 2008, v. 60, n. 1, p. 1, doi. 10.1159/000127972
- By:
- Publication type:
- Article
Long‐term efficacy and safety of erenumab in migraine prevention: Results from a 5‐year, open‐label treatment phase of a randomized clinical trial.
- Published in:
- European Journal of Neurology, 2021, v. 28, n. 5, p. 1716, doi. 10.1111/ene.14715
- By:
- Publication type:
- Article
Long‐term efficacy and safety of erenumab in patients with chronic migraine and acute medication overuse: A subgroup analysis.
- Published in:
- Headache: The Journal of Head & Face Pain, 2023, v. 63, n. 6, p. 730, doi. 10.1111/head.14536
- By:
- Publication type:
- Article
Long‐term efficacy and safety of erenumab in patients with chronic migraine in whom prior preventive treatments had failed: A subgroup analysis.
- Published in:
- Headache: The Journal of Head & Face Pain, 2022, v. 62, n. 5, p. 624, doi. 10.1111/head.14313
- By:
- Publication type:
- Article
Erenumab treatment for migraine prevention in Japanese patients: Efficacy and safety results from a Phase 3, randomized, double‐blind, placebo‐controlled study.
- Published in:
- Headache: The Journal of Head & Face Pain, 2021, v. 61, n. 6, p. 927, doi. 10.1111/head.14138
- By:
- Publication type:
- Article
Long‐term efficacy and safety during open‐label erenumab treatment in Japanese patients with episodic migraine.
- Published in:
- Headache: The Journal of Head & Face Pain, 2021, v. 61, n. 4, p. 653, doi. 10.1111/head.14096
- By:
- Publication type:
- Article
The Spectrum of Response to Erenumab in Patients With Episodic Migraine and Subgroup Analysis of Patients Achieving ≥50%, ≥75%, and 100% Response.
- Published in:
- Headache: The Journal of Head & Face Pain, 2020, v. 60, n. 9, p. 2026, doi. 10.1111/head.13929
- By:
- Publication type:
- Article
A Randomized Phase 2 Study of Erenumab for the Prevention of Episodic Migraine in Japanese Adults.
- Published in:
- Headache: The Journal of Head & Face Pain, 2019, v. 59, n. 10, p. 1731, doi. 10.1111/head.13652
- By:
- Publication type:
- Article
Evaluating the Psychometric Properties of the Migraine Functional Impact Questionnaire (MFIQ).
- Published in:
- Headache: The Journal of Head & Face Pain, 2019, v. 59, n. 8, p. 1253, doi. 10.1111/head.13569
- By:
- Publication type:
- Article
Development of a New Tool for Evaluating the Benefit of Preventive Treatments for Migraine on Functional Outcomes – The Migraine Functional Impact Questionnaire (MFIQ).
- Published in:
- Headache: The Journal of Head & Face Pain, 2018, v. 58, n. 10, p. 1612, doi. 10.1111/head.13420
- By:
- Publication type:
- Article
A Randomized, Double‐Blind, Placebo‐Controlled Study to Evaluate the Effect of Erenumab on Exercise Time During a Treadmill Test in Patients With Stable Angina.
- Published in:
- Headache: The Journal of Head & Face Pain, 2018, v. 58, n. 5, p. 715, doi. 10.1111/head.13316
- By:
- Publication type:
- Article
Use of existing electronic health care databases to evaluate medication safety in pregnancy: Triptan exposure in pregnancy as a case study.
- Published in:
- Pharmacoepidemiology & Drug Safety, 2018, v. 27, n. 12, p. 1309, doi. 10.1002/pds.4658
- By:
- Publication type:
- Article
Population Pharmacokinetics and Target Engagement of Natalizumab in Patients With Multiple Sclerosis.
- Published in:
- Journal of Clinical Pharmacology, 2017, v. 57, n. 8, p. 1017, doi. 10.1002/jcph.894
- By:
- Publication type:
- Article
Developmental Changes in the Molecular Weights of Polypeptides in the Human CNS That Carry the HNK-1 Epitope and Bind Phaseolus vulgaris Lectins.
- Published in:
- Journal of Neurochemistry, 1988, v. 50, n. 6, p. 1924, doi. 10.1111/j.1471-4159.1988.tb02498.x
- By:
- Publication type:
- Article
Expression of the Oligodendrocyte-Myelin Glycoprotein by Neurons in the Mouse Central Nervous System.
- Published in:
- Journal of Neurochemistry, 1998, v. 70, n. 4, p. 1704, doi. 10.1046/j.1471-4159.1998.70041704.x
- By:
- Publication type:
- Article
Efficacy and safety of erenumab in Japanese migraine patients with prior preventive treatment failure or concomitant preventive treatment: subgroup analyses of a phase 3, randomized trial.
- Published in:
- Journal of Headache & Pain, 2021, v. 22, n. 1, p. 1, doi. 10.1186/s10194-021-01313-8
- By:
- Publication type:
- Article
Reduction in acute migraine-specific and non-specific medication use in patients treated with erenumab: post-hoc analyses of episodic and chronic migraine clinical trials.
- Published in:
- Journal of Headache & Pain, 2021, v. 22, n. 1, p. 1, doi. 10.1186/s10194-021-01292-w
- By:
- Publication type:
- Article
Efficacy and safety of erenumab in women with a history of menstrual migraine.
- Published in:
- Journal of Headache & Pain, 2020, v. 21, n. 1, p. 1, doi. 10.1186/s10194-020-01167-6
- By:
- Publication type:
- Article
Letter to the editor: European headache federation guidelines on the use of monoclonal antibodies acting on the calcitonin gene-related peptide or its receptor for migraine prevention.
- Published in:
- 2019
- By:
- Publication type:
- Letter